Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
65.87
+2.72 (+4.31%)
Streaming Delayed Price
Updated: 10:25 AM EDT, Jun 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
25
26
27
28
29
30
31
32
Next >
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Gilead Sciences (GILD) Q3 2021 Earnings Call Transcript
October 29, 2021
GILD earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
October 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc...
Via
Benzinga
Gilead Trims Non-COVID Product Sales Outlook, Though Q3 Earnings Beat Street Estimates
October 29, 2021
Gilead Sciences Inc (NASDAQ: GILD) posted higher-than-expected Q3 earnings on strong demand for its COVID-19 antiviral treatment. Adjusted EPS increased 26% Y/Y to...
Via
Benzinga
Topics
Earnings
Exposures
COVID-19
Financial
Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass Estimates
October 28, 2021
Gilead Sciences came out with quarterly earnings of $2.65 per share.
Via
Talk Markets
GILD: Is This Biotech’s 4.2% Yield Healthy?
October 27, 2021
Gilead’s free cash flow hit a recent peak of $19.5 billion in 2015 before falling each of the next two years, settling around $7.5 billion in 2018.
Via
Talk Markets
Recap: Gilead Sciences Q3 Earnings
October 28, 2021
Gilead Sciences (NASDAQ:GILD) reported its Q3 earnings results on Thursday, October 28, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
Gilead Crushes Quarterly Forecasts and Raises Outlook For 2021; But Shares Dip
October 28, 2021
Gilead beat Wall Street's quarterly forecasts and raised its outlook for 2021.
Via
Investor's Business Daily
Pfizer Conceding Race in Hospitalized Covid Because of Todos Medical's Triple MOA Antiviral
October 28, 2021
Photo by Christina Victoria Craft on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a...
Via
Benzinga
Gilead Sciences Earnings Preview
October 27, 2021
Gilead Sciences (NASDAQ:GILD) is set to give its latest quarterly earnings report on Thursday, 2021-10-28. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays
October 27, 2021
It's much too early to count these companies out.
Via
The Motley Fool
The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children
October 26, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Sells Royalties Due On Cancer Drug Jemperli To Sagard For $250M...
Via
Benzinga
2 High-Yielding Stocks You Can Buy and Hold for Years
October 23, 2021
They pay more than double what the average S&P 500 stock yields.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Can Merck's Antiviral for COVID Succeed Where Gilead's Failed?
October 23, 2021
Signs point to yes, but it's still early in the game.
Via
The Motley Fool
Exposures
COVID-19
Vaccine Makers Slump As Oral Antivirals Begin To Take Center Stage
October 18, 2021
Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral...
Via
Talk Markets
Crispr: A Fallen Angel In Gene Editing
October 16, 2021
As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it...
Via
Talk Markets
The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies
October 15, 2021
Companies working on sorely needed Covid treatments are innovating to keep up.
Via
Investor's Business Daily
This Company Revolutionizes What Matters for Hospitals, Big Pharma and Health Insurers
October 14, 2021
You can perch on a 1-legged stool and balance precariously on 2, but if you want to settle in with comfort and safety, you need 3 sturdy legs. With its secure, cloud-based...
Via
Benzinga
Will Crispr Stock — And Its Cancer Drug — Rise After Allogene's Massive Fall?
October 12, 2021
Crispr is planning to begin a registrational test in the first quarter of 2022.
Via
Investor's Business Daily
Molnupiravir? Not So Fast. What About Tollovir? — Here's Why You Should Know What That Means
October 12, 2021
Photo by Martin Sanchez on Unsplash Merck (NYSE: MRK) announced last Friday impressive results from its COVID-19 antiviral, molnupiravir. As vaccines are requiring a third booster...
Via
Benzinga
Exposures
COVID-19
Biotech Stocks Are Lagging, Is It Time to Rebalance Your Healthcare Portfolio?
October 11, 2021
You may have seen that biotech stocks have been in a funk. The IBB has broken through the SMA-200 support line near $160 and it holds a perilous perch at $155, up only about 2.5% year-to-date. The IBB...
Via
Talk Markets
Why Gilead Sciences Investors Shouldn't Give Up on Remdesivir Just Yet
October 06, 2021
A new study shows it is highly effective in preventing deaths if taken early.
Via
The Motley Fool
Topics
Death
Exposures
COVID-19
Death
NanoViricides Leaps Forward in its Quest to Defeat COVID-19
October 05, 2021
Photo by Louis Reed on Unsplash Since the coronavirus pandemic started, scientists have worked to develop a vaccine to inoculate the population and stop the spread of COVID-19....
Via
Benzinga
Exposures
COVID-19
Tesla and Merck Give Investors Some Hope
October 04, 2021
Friday’s rally appears to have lost its momentum over the weekend because stock futures are trading lower before Monday’s open. China’s troubled real estate...
Via
Benzinga
Galapagos Assumes Responsibility Of Late-Stage Filgotinib Trial In Crohn's Disease
October 04, 2021
Galapagos NV (NASDAQ: GLPG) has randomized the last patient into the DIVERSITY Phase 3 study of filgotinib in the induction and maintenance of remission in...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
October 01, 2021
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...
Via
Benzinga
Gilead's Kite Files US Application To Expand Use Of Yescarta In Second-Line Setting
October 01, 2021
Kite Pharma, a Gilead Science Inc Company (NASDAQ: GILD), has submitted a supplemental marketing application to the FDA for Yescarta (axicabtagene ciloleucel...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
October 01, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...
Via
Benzinga
Exposures
Product Safety
3 Top Dividend Stocks Yielding More Than 4%
September 30, 2021
Make the most of your money with these generous income stocks.
Via
The Motley Fool
Merck's COVID-19 Antiviral Pill Effective Against Variants, Lab Studies Show
September 29, 2021
Merck & Co Inc (NYSE: MRK) presented a study at a medical conference early Wednesday for its experimental COVID-19 antiviral candidate. What Happened: Laboratory...
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
...
25
26
27
28
29
30
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.